{"entity":{"id":"nct04725994","kind":"trial","name":"Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer","aka":[],"tldr":"A phase 1/2 trial of IDX-1197+XELOX in gastric & gastro-oesophageal junction cancer, run by Idience Co., Ltd., active and no longer recruiting.","summary":"Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer is a phase 1/2 interventional study registered as NCT04725994 by Idience Co., Ltd., with 87 participants enrolled, started 2021-06-28 and due to reach its primary completion in 2026-07-31. Interventions recorded: IDX-1197+XELOX and IDX-1197+Irinotecan.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04725994","url":"https://clinicaltrials.gov/study/NCT04725994"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04725994","phase":"1/2","setting":"An Open-Label, International, Multicenter, Phase 1b/2a Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX (Capecitabine and Oxaliplatin) or Irinotecan in Patients With Advanced Gastric Cancer","sponsor":"Idience Co., Ltd.","enrolled":87,"outcomes":[]},"route":"/trials/nct04725994/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}]}}